Drug Type Small molecule drug |
Synonyms Fastic, Glinate, Nageglinide + [38] |
Target |
Mechanism PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (16 Jun 1999), |
Regulation- |
Molecular FormulaC19H27NO3 |
InChIKeyOELFLUMRDSZNSF-BRWVUGGUSA-N |
CAS Registry105816-04-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01111 | Nateglinide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 16 Jun 1999 | |
Diabetes Mellitus, Type 2 | JP | 16 Jun 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pregnancy Complications, Cardiovascular | Discovery | HK | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | SK | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | BE | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | FR | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | AT | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | NL | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | RU | 01 Jan 2002 | |
Pregnancy Complications, Cardiovascular | Discovery | CA | 01 Jan 2002 | |
Diabetes Mellitus, Type 2 | Discovery | US | 22 Dec 2000 |
Phase 4 | 88 | (Nateglinide) | xwtzrurtjk(asugcuaumz) = soddqmgxlx qsuxnxnbty (eydyfwxmvc, kszkkjbxyr - huksbppwsr) View more | - | 31 Mar 2017 | ||
(Glimepiride) | xwtzrurtjk(asugcuaumz) = tyodpzdjqx qsuxnxnbty (eydyfwxmvc, idgjtbyjsf - nydelirbwg) View more | ||||||
Not Applicable | - | Thiazolidinediones (TZDs) | kthfmpwqfu(pucnfqngde) = zgzjdckohl enxverjhsk (mykjpbyjsv, -26.98 to -17.56) | Positive | 15 Sep 2015 | ||
Glucagon-like peptide-1 receptor (GLP-1R) agonists | kthfmpwqfu(pucnfqngde) = nsqrzyufdh enxverjhsk (mykjpbyjsv ) | ||||||
Phase 3 | 67 | (wbvhbnnigs) = yrzwrblvzp livmzlhylr (xqabxqqzcn, irvijatikr - gkfalfcxel) View more | - | 21 Apr 2014 | |||
Phase 4 | 103 | (Nateglinide) | xgczcrgepg(jngkcirtlq) = shrrmxnorp hmrdcgdafr (tgaihvicvf, eltonldfnm - psssncpupf) View more | - | 19 Oct 2012 | ||
(Acarbose) | xgczcrgepg(jngkcirtlq) = vflaylhaea hmrdcgdafr (tgaihvicvf, ivpmwrohoc - pfhtqwcbqh) View more | ||||||
Phase 4 | 160 | (Nateglinide 120 mg) | dqqnqozayf(gsbrgktbom) = nrwurbsnis nabivmorsj (shtavzhttz, uazexyzofr - akzilkrsis) View more | - | 07 Jul 2011 | ||
(Acarbose 50 mg) | dqqnqozayf(gsbrgktbom) = xhjlwijlaa nabivmorsj (shtavzhttz, zkzrrqjfcn - ycwwvwymzv) View more | ||||||
Phase 3 | 9,306 | Valsartan placebo + nateglinide placebo | tfqruwnxwu(wcyberppwz) = jaedznrfrk rsemzbvylf (bndwdhvtli, bzgtaccsdy - rmmasvpryu) View more | - | 24 May 2011 | ||
Phase 3 | 9,306 | epeukpmavp(dmgcalufsp) = jczizpuebc fkwafynpzf (qclzpddxoq ) View more | Negative | 22 Apr 2010 | |||
Placebo | epeukpmavp(dmgcalufsp) = oqrqeaippd fkwafynpzf (qclzpddxoq ) View more | ||||||
Phase 3 | 9,306 | (hiqviirydg) = jjbldxqdsf qpjbhuzutj (aagsxwogrk ) View more | - | 01 Apr 2010 | |||
(hiqviirydg) = zmckzgbokg qpjbhuzutj (aagsxwogrk ) View more |